BDR Pharmaceuticals launch Cabozantinib to treat thyroid cancer
In several trials like Celestial (double-blind phase III trial), Phase III Meteor trials, Cabozantinib has shown better PFS (Progression-Free Survival).
In several trials like Celestial (double-blind phase III trial), Phase III Meteor trials, Cabozantinib has shown better PFS (Progression-Free Survival).
Incorporating multi-modality image guidance, Ethos therapy provides the ability to personalize the patient's treatment based on their anatomy and position at the time of treatment
The three-dose vaccine approved for EUA contains 2mg for each dose, whereas the two-dose plan will have 3mg in each dose.
One batch has 11.4 million units of Naproxen tablets out of which 0.9 million units that were released into the market were recalled
This low-cost and highly reliable technology will help in increasing testing in rural and tribal areas
Research collaboration covers multiple antibody research programs
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
The platform revolutionizes how providers deliver financial services by radically simplifying the patient financial experience
Crosscope and KFBIO join forces to lead digital transformation for pathology in India and emerging markets
This test can be run on commonly available qPCR cyclers, thereby, bypassing the need to perform expensive and time-consuming Next-Generation Sequencing
Subscribe To Our Newsletter & Stay Updated